Literature DB >> 9195084

Use and effectiveness of hypothermia blankets for febrile patients in the intensive care unit.

J O'Donnell1, P Axelrod, C Fisher, B Lorber.   

Abstract

We performed a prospective observational (noninterventional) study of hypothermia blanket use in a population of adult intensive care unit patients with body temperatures of > or = 102.5 degrees F. Thirty-nine of ninety-four febrile episodes (in 83 patients) were treated with hypothermia blankets. Logistic regression revealed that the strongest independent predictors of hypothermia blanket use were a temperature of > or = 103.5 degrees F (odds ratio [OR] = 17), mechanical ventilation (OR = 25), and acute central nervous system illness (OR = 7.5). Hospitalization in the medical intensive care unit was strongly associated with avoidance of this therapy (OR = 0.023). Treatment with a hypothermia blanket was ordered by a physician in only 15% of cases. The mean cooling rate was the same (0.028 degree F/h) for blanket-treated and control patients. Multivariate Cox regression and factorial and repeated measures of analysis of variance revealed that blanket treatment was not more effective than other cooling methods. However, this treatment was associated with more "zigzag" temperature fluctuations of > or = 3 degrees F (56% of blanket-treated patients vs. 18% of control patients; P < .001) and rebound hypothermia (18% vs. 0; P = .001). Hypothermia blanket therapy is primarily a nursing decision. We conclude that in addition to being no more effective than other cooling measures, hypothermia blanket therapy was associated with more temperature fluctuations and with more episodes of rebound hypothermia.

Entities:  

Mesh:

Year:  1997        PMID: 9195084     DOI: 10.1086/513660

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  13 in total

1.  Intravascular cooling for fever control.

Authors:  Stephan A Mayer
Journal:  Curr Neurol Neurosci Rep       Date:  2003-11       Impact factor: 5.081

Review 2.  Application of therapeutic hypothermia in the intensive care unit. Opportunities and pitfalls of a promising treatment modality--Part 2: Practical aspects and side effects.

Authors:  Kees H Polderman
Journal:  Intensive Care Med       Date:  2004-02-06       Impact factor: 17.440

3.  What We Do When We Suppress Fever.

Authors:  Philip A Mackowiak
Journal:  Curr Infect Dis Rep       Date:  2005-01       Impact factor: 3.725

Review 4.  Therapeutic temperature modulation in neurocritical care.

Authors:  Neeraj Badjatia
Journal:  Curr Neurol Neurosci Rep       Date:  2006-11       Impact factor: 5.081

5.  Intensive care unit management of fever following traumatic brain injury.

Authors:  Hilaire J Thompson; Catherine J Kirkness; Pamela H Mitchell
Journal:  Intensive Crit Care Nurs       Date:  2007-01-12       Impact factor: 3.072

6.  [Antipyretic strategies for acute stroke: a nationwide survey among German stroke units].

Authors:  B Kallmünzer; A Beck; S Schwab; R Kollmar
Journal:  Nervenarzt       Date:  2010-06       Impact factor: 1.214

Review 7.  Treatment of fever after stroke: conflicting evidence.

Authors:  Sylwia E Wrotek; Wieslaw E Kozak; David C Hess; Susan C Fagan
Journal:  Pharmacotherapy       Date:  2011-11       Impact factor: 4.705

8.  Fever management practices of neuroscience nurses: national and regional perspectives.

Authors:  Hilaire J Thompson; Catherine J Kirkness; Pamela H Mitchell; Deborah J Webb
Journal:  J Neurosci Nurs       Date:  2007-06       Impact factor: 1.230

9.  Predictors and clinical implications of shivering during therapeutic normothermia.

Authors:  Neeraj Badjatia; Robert G Kowalski; J Michael Schmidt; Marc E Voorhees; Jan Claassen; Noeleen D Ostapkovich; Mary Presciutti; E Sander Connolly; David Palestrant; Augusto Parra; Stephan A Mayer
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

10.  Continuous low dose diclofenac sodium infusion to control fever in neurosurgical critical care.

Authors:  Manuela Cormio; Giuseppe Citerio
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.